Histone deacetylase inhibitor apicidin-mediated drug resistance: Involvement of P-glycoprotein

Biochemical and Biophysical Research Communications

Volumn 368, Issue 4, 2008, Pages 959-964

  Kim, Yong Kee ^a   Kim, Nam Hyun ^a   Hwang, Jee Won ^a   Song, Yong Jin ^a   Park, Yeon Suk ^b   Seo, Dong Wan ^c   Lee, Hoi Young ^d   Choi, Wahn Soo ^e   Han, Jeung Whan ^f   Kim, Su Nam ^b  

^a Kwandong University College of Medicine   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Kangwon National University   (South Korea)

^d Konyang University   (South Korea)

^e Konkuk University School of Medicine   (South Korea)

^f Sungkyunkwan University   (South Korea)

Author keywords

Apicidin; Apoptosis; HDAC inhibitor; Multidrug resistance; P glycoprotein

Indexed keywords

APICIDIN; GLYCOPROTEIN P; HISTONE DEACETYLASE INHIBITOR; PACLITAXEL; RHODAMINE 123; VERAPAMIL;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; HELA CELL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION;

CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; HELA CELLS; HISTONE DEACETYLASES; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; PEPTIDES, CYCLIC; RHODAMINE 123;

EID: 40049111860     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.02.013     Document Type: Article

References (26)

1. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13 (2001) 477-483
2. Piekarz R., and Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. 10 (2004) 2289-2298
3. Han J.W., Ahn S.H., Park S.H., Wang S.Y., Bae G.U., Seo D.W., Kwon H.K., Hong S., Lee H.Y., Lee Y.W., and Lee H.W. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 60 (2000) 6068-6074
4. Kwon S.H., Ahn S.H., Kim Y.K., Bae G.U., Yoon J.W., Hong S., Lee H.Y., Lee Y.W., Lee H.W., and Han J.W. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem. 277 (2002) 2073-2080
5. Munster P.N., Troso-Sandoval T., Rosen N., Rifkind R., Marks P.A., and Richon V.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61 (2001) 8492-8497
6. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., and Sausville E.A. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 23 (2005) 3912-3922
7. Carducci M.A., Gilbert J., Bowling M.K., Noe D., Eisenberger M.A., Sinibaldi V., Zabelina Y., Chen T.L., Grochow L.B., and Donehower R.C. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. 7 (2001) 3047-3055
8. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., Lin T.S., Liu S., Sklenar A.R., Davis M.E., Lucas D.M., Fischer B., Shank R., Tejaswi S.L., Binkley P., Wright J., Chan K.K., and Grever M.R. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105 (2005) 959-967
9. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
10. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 361-398
11. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 (2002) 48-58
12. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 40 Suppl. (1997) S3-S8
13. El-Osta A., Kantharidis P., Zalcberg J.R., and Wolffe A.P. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol. Cell. Biol. 22 (2002) 1844-1857
14. Nakayama M., Wada M., Harada T., Nagayama J., Kusaba H., Ohshima K., Kozuru M., Komatsu H., Ueda R., and Kuwano M. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 92 (1998) 4296-4307
15. Kantharidis P., El-Osta A., deSilva M., Wall D.M., Hu X.F., Slater A., Nadalin G., Parkin J.D., and Zalcberg J.R. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin. Cancer Res. 3 (1997) 2025-2032
16. Baker E.K., Johnstone R.W., Zalcberg J.R., and El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24 (2005) 8061-8075
17. Tabe Y., Konopleva M., Contractor R., Munsell M., Schober W.D., Jin L., Tsutsumi-Ishii Y., Nagaoka I., Igari J., and Andreeff M. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 107 (2006) 1546-1554
18. Robey R.W., Zhan Z., Piekarz R.L., Kayastha G.L., Fojo T., and Bates S.E. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin. Cancer Res. 12 (2006) 1547-1555
19. Kim Y.K., Lee E.K., Kang J.K., Kim J.A., You J.S., Park J.H., Seo D.W., Hwang J.W., Kim S.N., Lee H.Y., Lee H.W., and Han J.W. Activation of NF-kappaB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: its implication for resistance to apoptosis. Cell Death Differ. 13 (2006) 2033-2041
20. Kim Y.K., Seo D.W., Kang D.W., Lee H.Y., Han J.W., and Kim S.N. Involvement of HDAC1 and the PI3K/PKC signaling pathways in NF-kappaB activation by the HDAC inhibitor apicidin. Biochem. Biophys. Res. Commun. 347 (2006) 1088-1093
21. Kim Y.K., Han J.W., Woo Y.N., Chun J.K., Yoo J.Y., Cho E.J., Hong S., Lee H.Y., Lee Y.W., and Lee H.W. Expression of p21(WAF1/Cip1) through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinase-PKC epsilon signaling pathway. Oncogene 22 (2003) 6023-6031
22. Goldie J.H., and Coldman A.J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 44 (1984) 3643-3653
23. Abolhoda A., Wilson A.E., Ross H., Danenberg P.V., Burt M., and Scotto K.W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 5 (1999) 3352-3356
24. Hu X.F., Slater A., Kantharidis P., Rischin D., Juneja S., Rossi R., Lee G., Parkin J.D., and Zalcberg J.R. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood 93 (1999) 4086-4095
25. Jin S., and Scotto K.W. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell. Biol. 18 (1998) 4377-4384
26. Han J.W., Ahn S.H., Kim Y.K., Bae G.U., Yoon J.W., Hong S., Lee H.Y., Lee Y.W., and Lee H.W. Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J. Biol. Chem. 276 (2001) 42084-42090